Alvotech Enters Further US Partnership Agreement for Adalimumab Biosimilar

On 19 April 2024, Alvotech announced that it has entered a long-term agreement with an unnamed strategic partner to market in the US its high concentration interchangeable adalimumab-ryvk (AVT02), biosimilar to AbbVie’s Humira®, which received FDA approval in February 2023.  Teva will continue to commercialise adalimumab-ryvk under the SIMLANDI® brand in the US pursuant to its existing strategic partnership with Alvotech, which remains unchanged.